Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy
Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric...
Gespeichert in:
| Veröffentlicht in: | Virchows Archiv : an international journal of pathology 2021-06, Vol.478 (6), p.1161-1171 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1171 |
|---|---|
| container_issue | 6 |
| container_start_page | 1161 |
| container_title | Virchows Archiv : an international journal of pathology |
| container_volume | 478 |
| creator | Yoshida, Hiroshi Nishikawa, Tadaaki Matsumoto, Koji Mori, Masahiko Hirashima, Yasuyuki Takehara, Kazuhiro Ariyoshi, Kazuya Hasegawa, Kosei Yonemori, Kan |
| description | Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric and breast cancer, and to propose requirements for HER2 testing for UCS. Eighty-nine specimens from 84 patients with metastatic/recurrent UCS were prospectively collected from May 2018 to July 2020. We performed HER2 immunohistochemistry (IHC) for 89 specimens and FISH for 44 specimens. HER2 expression details and HER2 score were evaluated according to the latest ASCO/CAP criteria for gastric (2016) and breast cancer (2018). HER2 IHC scores according to the gastric cancer criteria were 0 in 31 cases (35%), 1+ in 26 (29%), 2+ in 22 (25%), and 3+ in 10 cases (11%) of the 89 specimens. A lateral/basolateral membranous staining pattern was observed in 28/32 (88%) specimens with HER2 scores of 2+/3+. HER2 intratumoral heterogeneity was identified in 28/32 (88%) of the specimens with HER2 scores of 2+/3+. The overall concordance rate of HER2 score was 70% between the gastric and breast criteria. FISH revealed
HER2
gene amplification in 10/44 (23%) specimens containing only lateral/basolateral membranous staining pattern. Based on the histopathological features of HER2 expression in UCS, a scoring system that accepts lateral/basolateral staining patterns should be applied. Furthermore, we proposed specific requirements for UCS testing, including specimen selection, scoring system, and calculating the proportion of HER2-positive cells. |
| doi_str_mv | 10.1007/s00428-021-03017-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2476851147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2540467955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-2225911f6a3a88647a77d913f23666af6737304df24e0e0841b4035adcabca363</originalsourceid><addsrcrecordid>eNp9kV9LHDEUxUOp1K3tF-iDBPriy9SbP5PM-iai3YIglPY5ZGfurJGZZEwyUj9Dv7TZXVvBB58u9-Z3Tg4cQr4w-MYA9GkCkLypgLMKBDBd1e_IgknBKy5AvycLWMq6UoLpQ_IxpTsoZMPUB3IohOSCcb0gf1cu5TDZfBuGsHGtHWiPNs8REw09XV3-5DQ8YMQ_UzklFzx1ns4Zo_NIWxtb50MqI4z2jE4xTGUrHiHSiPeziziiz2kr2nllTNn5zQ7INm4wY0fzLUY7PX4iB70dEn5-nkfk99Xlr4tVdX3z_cfF-XXVSslyxTmvl4z1ygrbNEpqq3W3ZKLnQille6WFFiC7nksEhEaytQRR266169YKJY7Iyd63xL2fSyAzutTiMFiPYU6GS62amjGpC_r1FXoX5uhLOsNrCVLpZV0Xiu-pNoaUIvZmim608dEwMNuqzL4qUwowu6rMVnT8bD2vR-z-S_51UwCxB1J58huML3-_YfsEuw-f2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2540467955</pqid></control><display><type>article</type><title>Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy</title><source>SpringerLink Journals</source><creator>Yoshida, Hiroshi ; Nishikawa, Tadaaki ; Matsumoto, Koji ; Mori, Masahiko ; Hirashima, Yasuyuki ; Takehara, Kazuhiro ; Ariyoshi, Kazuya ; Hasegawa, Kosei ; Yonemori, Kan</creator><creatorcontrib>Yoshida, Hiroshi ; Nishikawa, Tadaaki ; Matsumoto, Koji ; Mori, Masahiko ; Hirashima, Yasuyuki ; Takehara, Kazuhiro ; Ariyoshi, Kazuya ; Hasegawa, Kosei ; Yonemori, Kan</creatorcontrib><description>Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric and breast cancer, and to propose requirements for HER2 testing for UCS. Eighty-nine specimens from 84 patients with metastatic/recurrent UCS were prospectively collected from May 2018 to July 2020. We performed HER2 immunohistochemistry (IHC) for 89 specimens and FISH for 44 specimens. HER2 expression details and HER2 score were evaluated according to the latest ASCO/CAP criteria for gastric (2016) and breast cancer (2018). HER2 IHC scores according to the gastric cancer criteria were 0 in 31 cases (35%), 1+ in 26 (29%), 2+ in 22 (25%), and 3+ in 10 cases (11%) of the 89 specimens. A lateral/basolateral membranous staining pattern was observed in 28/32 (88%) specimens with HER2 scores of 2+/3+. HER2 intratumoral heterogeneity was identified in 28/32 (88%) of the specimens with HER2 scores of 2+/3+. The overall concordance rate of HER2 score was 70% between the gastric and breast criteria. FISH revealed
HER2
gene amplification in 10/44 (23%) specimens containing only lateral/basolateral membranous staining pattern. Based on the histopathological features of HER2 expression in UCS, a scoring system that accepts lateral/basolateral staining patterns should be applied. Furthermore, we proposed specific requirements for UCS testing, including specimen selection, scoring system, and calculating the proportion of HER2-positive cells.</description><identifier>ISSN: 0945-6317</identifier><identifier>EISSN: 1432-2307</identifier><identifier>DOI: 10.1007/s00428-021-03017-5</identifier><identifier>PMID: 33423127</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibodies ; Breast cancer ; Criteria ; ErbB-2 protein ; Gastric cancer ; Gene amplification ; Heterogeneity ; Immunohistochemistry ; Medicine ; Medicine & Public Health ; Metastases ; Original Article ; Pathology ; Staining ; Test procedures ; Uterus</subject><ispartof>Virchows Archiv : an international journal of pathology, 2021-06, Vol.478 (6), p.1161-1171</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-2225911f6a3a88647a77d913f23666af6737304df24e0e0841b4035adcabca363</citedby><cites>FETCH-LOGICAL-c441t-2225911f6a3a88647a77d913f23666af6737304df24e0e0841b4035adcabca363</cites><orcidid>0000-0002-7569-7813</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00428-021-03017-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00428-021-03017-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33423127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshida, Hiroshi</creatorcontrib><creatorcontrib>Nishikawa, Tadaaki</creatorcontrib><creatorcontrib>Matsumoto, Koji</creatorcontrib><creatorcontrib>Mori, Masahiko</creatorcontrib><creatorcontrib>Hirashima, Yasuyuki</creatorcontrib><creatorcontrib>Takehara, Kazuhiro</creatorcontrib><creatorcontrib>Ariyoshi, Kazuya</creatorcontrib><creatorcontrib>Hasegawa, Kosei</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><title>Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy</title><title>Virchows Archiv : an international journal of pathology</title><addtitle>Virchows Arch</addtitle><addtitle>Virchows Arch</addtitle><description>Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric and breast cancer, and to propose requirements for HER2 testing for UCS. Eighty-nine specimens from 84 patients with metastatic/recurrent UCS were prospectively collected from May 2018 to July 2020. We performed HER2 immunohistochemistry (IHC) for 89 specimens and FISH for 44 specimens. HER2 expression details and HER2 score were evaluated according to the latest ASCO/CAP criteria for gastric (2016) and breast cancer (2018). HER2 IHC scores according to the gastric cancer criteria were 0 in 31 cases (35%), 1+ in 26 (29%), 2+ in 22 (25%), and 3+ in 10 cases (11%) of the 89 specimens. A lateral/basolateral membranous staining pattern was observed in 28/32 (88%) specimens with HER2 scores of 2+/3+. HER2 intratumoral heterogeneity was identified in 28/32 (88%) of the specimens with HER2 scores of 2+/3+. The overall concordance rate of HER2 score was 70% between the gastric and breast criteria. FISH revealed
HER2
gene amplification in 10/44 (23%) specimens containing only lateral/basolateral membranous staining pattern. Based on the histopathological features of HER2 expression in UCS, a scoring system that accepts lateral/basolateral staining patterns should be applied. Furthermore, we proposed specific requirements for UCS testing, including specimen selection, scoring system, and calculating the proportion of HER2-positive cells.</description><subject>Antibodies</subject><subject>Breast cancer</subject><subject>Criteria</subject><subject>ErbB-2 protein</subject><subject>Gastric cancer</subject><subject>Gene amplification</subject><subject>Heterogeneity</subject><subject>Immunohistochemistry</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Original Article</subject><subject>Pathology</subject><subject>Staining</subject><subject>Test procedures</subject><subject>Uterus</subject><issn>0945-6317</issn><issn>1432-2307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kV9LHDEUxUOp1K3tF-iDBPriy9SbP5PM-iai3YIglPY5ZGfurJGZZEwyUj9Dv7TZXVvBB58u9-Z3Tg4cQr4w-MYA9GkCkLypgLMKBDBd1e_IgknBKy5AvycLWMq6UoLpQ_IxpTsoZMPUB3IohOSCcb0gf1cu5TDZfBuGsHGtHWiPNs8REw09XV3-5DQ8YMQ_UzklFzx1ns4Zo_NIWxtb50MqI4z2jE4xTGUrHiHSiPeziziiz2kr2nllTNn5zQ7INm4wY0fzLUY7PX4iB70dEn5-nkfk99Xlr4tVdX3z_cfF-XXVSslyxTmvl4z1ygrbNEpqq3W3ZKLnQille6WFFiC7nksEhEaytQRR266169YKJY7Iyd63xL2fSyAzutTiMFiPYU6GS62amjGpC_r1FXoX5uhLOsNrCVLpZV0Xiu-pNoaUIvZmim608dEwMNuqzL4qUwowu6rMVnT8bD2vR-z-S_51UwCxB1J58huML3-_YfsEuw-f2g</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Yoshida, Hiroshi</creator><creator>Nishikawa, Tadaaki</creator><creator>Matsumoto, Koji</creator><creator>Mori, Masahiko</creator><creator>Hirashima, Yasuyuki</creator><creator>Takehara, Kazuhiro</creator><creator>Ariyoshi, Kazuya</creator><creator>Hasegawa, Kosei</creator><creator>Yonemori, Kan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7569-7813</orcidid></search><sort><creationdate>20210601</creationdate><title>Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy</title><author>Yoshida, Hiroshi ; Nishikawa, Tadaaki ; Matsumoto, Koji ; Mori, Masahiko ; Hirashima, Yasuyuki ; Takehara, Kazuhiro ; Ariyoshi, Kazuya ; Hasegawa, Kosei ; Yonemori, Kan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-2225911f6a3a88647a77d913f23666af6737304df24e0e0841b4035adcabca363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Breast cancer</topic><topic>Criteria</topic><topic>ErbB-2 protein</topic><topic>Gastric cancer</topic><topic>Gene amplification</topic><topic>Heterogeneity</topic><topic>Immunohistochemistry</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Original Article</topic><topic>Pathology</topic><topic>Staining</topic><topic>Test procedures</topic><topic>Uterus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Hiroshi</creatorcontrib><creatorcontrib>Nishikawa, Tadaaki</creatorcontrib><creatorcontrib>Matsumoto, Koji</creatorcontrib><creatorcontrib>Mori, Masahiko</creatorcontrib><creatorcontrib>Hirashima, Yasuyuki</creatorcontrib><creatorcontrib>Takehara, Kazuhiro</creatorcontrib><creatorcontrib>Ariyoshi, Kazuya</creatorcontrib><creatorcontrib>Hasegawa, Kosei</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Virchows Archiv : an international journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Hiroshi</au><au>Nishikawa, Tadaaki</au><au>Matsumoto, Koji</au><au>Mori, Masahiko</au><au>Hirashima, Yasuyuki</au><au>Takehara, Kazuhiro</au><au>Ariyoshi, Kazuya</au><au>Hasegawa, Kosei</au><au>Yonemori, Kan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy</atitle><jtitle>Virchows Archiv : an international journal of pathology</jtitle><stitle>Virchows Arch</stitle><addtitle>Virchows Arch</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>478</volume><issue>6</issue><spage>1161</spage><epage>1171</epage><pages>1161-1171</pages><issn>0945-6317</issn><eissn>1432-2307</eissn><abstract>Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric and breast cancer, and to propose requirements for HER2 testing for UCS. Eighty-nine specimens from 84 patients with metastatic/recurrent UCS were prospectively collected from May 2018 to July 2020. We performed HER2 immunohistochemistry (IHC) for 89 specimens and FISH for 44 specimens. HER2 expression details and HER2 score were evaluated according to the latest ASCO/CAP criteria for gastric (2016) and breast cancer (2018). HER2 IHC scores according to the gastric cancer criteria were 0 in 31 cases (35%), 1+ in 26 (29%), 2+ in 22 (25%), and 3+ in 10 cases (11%) of the 89 specimens. A lateral/basolateral membranous staining pattern was observed in 28/32 (88%) specimens with HER2 scores of 2+/3+. HER2 intratumoral heterogeneity was identified in 28/32 (88%) of the specimens with HER2 scores of 2+/3+. The overall concordance rate of HER2 score was 70% between the gastric and breast criteria. FISH revealed
HER2
gene amplification in 10/44 (23%) specimens containing only lateral/basolateral membranous staining pattern. Based on the histopathological features of HER2 expression in UCS, a scoring system that accepts lateral/basolateral staining patterns should be applied. Furthermore, we proposed specific requirements for UCS testing, including specimen selection, scoring system, and calculating the proportion of HER2-positive cells.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33423127</pmid><doi>10.1007/s00428-021-03017-5</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7569-7813</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0945-6317 |
| ispartof | Virchows Archiv : an international journal of pathology, 2021-06, Vol.478 (6), p.1161-1171 |
| issn | 0945-6317 1432-2307 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2476851147 |
| source | SpringerLink Journals |
| subjects | Antibodies Breast cancer Criteria ErbB-2 protein Gastric cancer Gene amplification Heterogeneity Immunohistochemistry Medicine Medicine & Public Health Metastases Original Article Pathology Staining Test procedures Uterus |
| title | Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histopathological%20features%20of%20HER2%20overexpression%20in%20uterine%20carcinosarcoma:%20proposal%20for%20requirements%20in%20HER2%20testing%20for%20targeted%20therapy&rft.jtitle=Virchows%20Archiv%20:%20an%20international%20journal%20of%20pathology&rft.au=Yoshida,%20Hiroshi&rft.date=2021-06-01&rft.volume=478&rft.issue=6&rft.spage=1161&rft.epage=1171&rft.pages=1161-1171&rft.issn=0945-6317&rft.eissn=1432-2307&rft_id=info:doi/10.1007/s00428-021-03017-5&rft_dat=%3Cproquest_cross%3E2540467955%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2540467955&rft_id=info:pmid/33423127&rfr_iscdi=true |